Health Rounds: Shingles Vaccine Linked to Lower Dementia Mortality

by Dr Natalie Singh - Health Editor
0 comments

“`html





Shingles Vaccine Linked to Reduced Dementia Risk

shingles Vaccine May Reduce Risk of Dementia,Study Finds

A recent study published in the journal neurology suggests a potential link between the shingles vaccine and a reduced risk of dementia,including Alzheimer’s disease. Researchers found that individuals who received the recombinant zoster vaccine (RZV), shingrix, experienced a significantly lower incidence of dementia compared to those who did not receive the vaccine. This finding adds to a growing body of evidence suggesting the vaccine’s benefits extend beyond preventing shingles.

Understanding the Connection: Shingles, Immunity, and Dementia

The connection between the shingles vaccine and dementia risk isn’t promptly obvious. The key lies in the vaccine’s impact on the immune system. Shingles, caused by the reactivation of the varicella-zoster virus (the same virus that causes chickenpox), is associated with inflammation. Chronic inflammation is increasingly recognized as a contributing factor in the growth of neurodegenerative diseases like Alzheimer’s disease.

The Shingrix vaccine boosts immunity to the varicella-zoster virus, potentially reducing inflammation and protecting against nerve damage. Researchers hypothesize that this immune boost may also have a protective effect on the brain,reducing the risk of dementia. It’s critically important to note that this is a complex relationship and further research is needed to fully understand the mechanisms at play.

How the Study Was Conducted

The study, conducted by researchers at the University of Washington, analyzed data from over 96,000 individuals aged 65 and older enrolled in medicare. Researchers compared the incidence of dementia diagnoses among those who received the Shingrix vaccine between 2017 and 2022 with those who did not. The study controlled for factors known to influence dementia risk, such as age, sex, race, and pre-existing health conditions like diabetes and heart disease. Source: Neurology

The results showed a 30% reduction in dementia diagnoses among vaccinated individuals over a four-year follow-up period. This reduction was observed across different types of dementia,including alzheimer’s disease and vascular dementia.

Shingrix: What You Need to know

Shingrix is a non-live, recombinant subunit vaccine approved by the Food and Drug Administration (FDA) for the prevention of shingles in adults aged 50 and older. It’s administered in two doses,two to six months apart. Source: Centers for Disease Control and Prevention (CDC)

  • effectiveness: Shingrix is over 90% effective in preventing shingles and its complications.
  • Side Effects: Common side effects include pain, redness, and swelling at the injection site, and also fatigue, muscle aches, and headache. These side effects are typically mild to moderate and resolve within a few days.
  • Who Should Get Vaccinated: The CDC recommends that healthy adults aged 50 and older receive two doses of Shingrix, even if they have had shingles or received the older, live-virus shingles vaccine (Zostavax).

Important Considerations and Future Research

While the study findings are promising,it’s crucial to remember that correlation does not equal causation. This study demonstrates an association between the shingles vaccine and reduced dementia risk,but it doesn’t prove that the vaccine directly prevents dementia. Further research, including randomized controlled trials, is needed to confirm these findings and elucidate the underlying mechanisms.

Experts emphasize that vaccination against shingles should be considered as part of a extensive approach to brain health, which includes maintaining a healthy lifestyle, managing cardiovascular risk factors, and engaging in mentally stimulating activities.

Key Takeaways

Related Posts

Leave a Comment